Plus500 does not provide CFD services to residents of the United States. Visit our U.S. website at

Markets React to UK Vaccine Approval

Plus500 | Thursday 03 December 2020

FTSE100 (UK100) futures jumped 1.1% yesterday and Pfizer (PFE) climbed as high as 2.3%  to $41.32 during yesterday’s trading following COVID-19 vaccine approval before closing at $40.72.

UK vaccine

Yesterday, the UK’s health agency, the MHRA, announced approval of Pfizer and BioNtech’s request for emergency approval for their COVID-19 vaccine. This makes the UK the first country to have approved any Coronavirus vaccine, which will begin being administered as early as next week.

Currently, there are 800,000 doses on the way to the UK with elderly people and their caretakers slated to be the first to receive this vaccine. This comes on the heels of governments across Europe and some American localities imposing new lockdown restrictions to help curb the spread of the virus. In reaction to this long anticipated COVID vaccine, some shares, commodities, and index futures moved higher during yesterday’s trading.

Vaccine developers saw a boost in share prices, such as Moderna (MRNA), which closed 1.4% higher. Even Astrazeneca (AZN-L), who need to retest their vaccines after inconsistent testing reports, notched 1.2% higher to £7972 per share before closing at £7,926.

Oil Climbs Following Vaccine Approval

Oil futures traded higher yesterday as markets looked beyond the pandemic to an eventual softening of lockdowns, following the vaccine news. Since March of this year, Oil has struggled to return to pre-pandemic valuations. 

American West Texas Intermediate Oil (CL) futures rose 3.5% to a high of $45.88 during yesterday’s trading before closing the day at $44.94. North Sea Brent Crude (EB) futures rose 3.7% to a high of $48.74 during yesterday’s trading, yet closed the day at $47.98. This also pushed British Oil and gas producer, BP (BP-L) to close 4.7% higher during yesterday’s trading.

This vaccine approval indicates a turning point in the fight against the Coronavirus. While it may be some time before full populations can be immunized, leaving traders to speculate on the potential for future market volatility.

This information is written by Plus500 Ltd. The information is provided for general purposes only, and does not take into account any personal circumstances or objectives. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice. No representation or warranty is given as to the accuracy or completeness of this information. It does not constitute financial, investment or other advice on which you can rely. Any references to past performance, historical returns, future projections, and statistical forecasts are no guarantee of future returns or future performance. Plus500 will not be held responsible for any use that may be made of this information and for any consequences that may result from such use. Hence, any person acting based on this information does so at their own discretion. The information has not been prepared in accordance with legal requirements designed to promote the independence of investment research.

Need Help?
24/7 Support